I am excited to announce what I’ve been working on for the past 2 years. General Control is a mandate to develop programmable therapies that make durable, reversible adjustments to gene expression - epigenetically activating or silencing multiple targets at once. In the past 16 months, we: - Achieved a technical leap in epigenetic editing by engineering an editor library that outperforms leading published systems on potency and durability - Launched a multi-target partnership with Novo Nordisk - Generated animal data for 3 different programs and developed a lead we are now ready to translate to the clinic - Raised 5.5M pre-seed from @age1vc @fiftyyears @tmrohan @mollyfmielke and others